Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012

Apr 24, 2012, 07:14 ET from Simcere Pharmaceutical Group

NANJING, China, April 24, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Wednesday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

International toll:                       


United States toll-free:                            


United States toll:                       


China Domestic toll:                     


China Domestic mobile toll:         


Hong Kong toll:                            


Please ask to be connected to Q1 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 73500159.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:                          


United States toll:                     


The passcode for replay participants is 73500159. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit

Investor and Media Contacts:


In Nanjing:                                                                  

In the United States:

Yehong Zhang                                                             

Cindy Zheng


Brunswick Group

Simcere Pharmaceutical Group                                     

Tel: 1-212-333-3810

Tel: 86-25-8556-6666 ext. 8811

In Beijing:                                                                   

In Hong Kong:

Yue Yu                                                                        

Joseph Lo Chi-Lun

Brunswick Group                                                          

Brunswick Group

Tel: 86-10-5960-8600                                                     

Tel: 852-3512-5000 




SOURCE Simcere Pharmaceutical Group